YTTERBIUM YB 169 DTPA Drug Patent Profile
Which patents cover Ytterbium Yb 169 Dtpa, and what generic alternatives are available?
Ytterbium Yb 169 Dtpa is a drug marketed by 3M and is included in one NDA.
The generic ingredient in YTTERBIUM YB 169 DTPA is pentetate calcium trisodium yb-169. There is one drug master file entry for this compound. Additional details are available on the pentetate calcium trisodium yb-169 profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for YTTERBIUM YB 169 DTPA?
- What are the global sales for YTTERBIUM YB 169 DTPA?
- What is Average Wholesale Price for YTTERBIUM YB 169 DTPA?
Summary for YTTERBIUM YB 169 DTPA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Applications: | 47 |
| DailyMed Link: | YTTERBIUM YB 169 DTPA at DailyMed |
US Patents and Regulatory Information for YTTERBIUM YB 169 DTPA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3m | YTTERBIUM YB 169 DTPA | pentetate calcium trisodium yb-169 | INJECTABLE;INJECTION | 017518-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
